bevacizumab + eribulin + paclitaxel

This represents a treatment strategy rather than a single combination therapy. The literature describes various approaches using these three drugs for HER2-negative metastatic breast cancer (MBC), including: 1) First-line bevacizumab + paclitaxel followed by eribulin, 2) First-line eribulin + bevacizumab followed by paclitaxel, or 3) Sequential use of these agents. Bevacizumab is an antiangiogenic monoclonal antibody targeting VEGF, while eribulin and paclitaxel are microtubule-targeting agents with different mechanisms. Clinical studies have evaluated the efficacy and safety of various combinations and sequences of these drugs, particularly for HER2-negative metastatic breast cancer.